125 related articles for article (PubMed ID: 18441450)
41. Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Spence JD; Munoz CE; Hendricks L; Latchinian L; Khouri HE
Am J Cardiol; 1995 Jul; 76(2):80A-83A. PubMed ID: 7604806
[TBL] [Abstract][Full Text] [Related]
42. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia.
Yoshino G; Hirano T; Kazumi T; Takemoto M; Ohashi N
J Atheroscler Thromb; 2003; 10(6):343-7. PubMed ID: 15037823
[TBL] [Abstract][Full Text] [Related]
43. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.
Oguz A; Uzunlulu M
Int Heart J; 2008 May; 49(3):303-11. PubMed ID: 18612188
[TBL] [Abstract][Full Text] [Related]
44. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease.
Yasuda G; Kuji T; Hasegawa K; Ogawa N; Shimura G; Ando D; Umemura S
Ren Fail; 2004 Jul; 26(4):411-8. PubMed ID: 15462110
[TBL] [Abstract][Full Text] [Related]
47. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
Peters TK
Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
49. [Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes].
Sarano NE; Kozlov SG; Tvorogova MG; Liakishev AA; Naumov VG
Kardiologiia; 2003; 43(4):30-5. PubMed ID: 12891248
[TBL] [Abstract][Full Text] [Related]
50. [The effect of early fluvastatin therapy on inflammatory factors in acute coronary syndrome].
Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM; Peng J
Zhonghua Nei Ke Za Zhi; 2005 Mar; 44(3):184-7. PubMed ID: 15840256
[TBL] [Abstract][Full Text] [Related]
51. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Papadakis JA; Ganotakis ES; Jagroop IA; Winder AF; Mikhailidis DP
Int J Cardiol; 1999 Jun; 69(3):237-44. PubMed ID: 10402106
[TBL] [Abstract][Full Text] [Related]
52. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
53. [Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia].
Chi DS; Jin FX; Yang SG; Su YW; Ge B; Zhang J; Zhang Y; Liu YL
Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1109-11. PubMed ID: 12480587
[TBL] [Abstract][Full Text] [Related]
54. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
[TBL] [Abstract][Full Text] [Related]
55. Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1.
Guan JZ; Murakami H; Yamato K; Tanabe J; Matsui J; Tamasawa N; Suda T
J Atheroscler Thromb; 2004; 11(2):56-61. PubMed ID: 15153664
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
[TBL] [Abstract][Full Text] [Related]
57. A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects.
Eagles CJ; Kendall MJ; Maxwell S
Br J Clin Pharmacol; 1996 May; 41(5):381-7. PubMed ID: 8735678
[TBL] [Abstract][Full Text] [Related]
58. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
[TBL] [Abstract][Full Text] [Related]
59. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
60. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
Herd JA; Ballantyne CM; Farmer JA; Ferguson JJ; Jones PH; West MS; Gould KL; Gotto AM
Am J Cardiol; 1997 Aug; 80(3):278-86. PubMed ID: 9264419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
